
BBMT/CellTherapy Physician @ Ochsner-LSU FWCC | Fellowship @StanfordBMT_CT|Tweets, RT’s are personal opinions and not endorsements
Albuquerque, NM
Joined January 2017
- Tweets101
- Following334
- Followers183
- Likes767
Shashank Cingam retweeted
Thanks @US_FDA for co-hosting the FDA-ASH Workshop! The past two days, participants explored the FDA’s role in #hematology product development through panels and case discussions, fostering dialogue on key regulatory issues.
ow.ly/4io250X4yoc
#HemeOnc @FDAOncology
Shashank Cingam retweeted
It’s #ASHCRTI week in LaJolla.
@ASH_hematology
A week full of redoing study proposals, mentorship and forming life long professional friendships for participants and faculty - 28 trainees across classical and malignant hematology
#ASHTrainee
Shashank Cingam retweeted
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia - Kidney International kidney-international.org/art…
Dr.Sindhu Devarashetty @LSUHS presenting updates on Ovarian Cancer #BestofASCO2025 @binaytara #Shreveport
Dr. Yu Cao @utswcancer presenting updates on Head and neck cancer #BestofASCO2025 @binaytara #Shreveport
1
154
Dr.Marc Matrana @OchsnerHealth kicks-off the Best of ASCO 2025 in Shreveport #BestofASCO2025 #Shreveport @binaytara
Dr.Brian Halbert @OchsnerHealth presenting updates in Baldder Cancer at #BestofASCO2025 @binaytara #Shreveport
Shashank Cingam retweeted
“Nonclassical” myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. ow.ly/5knJ50W1ftQ #myeloidneoplasia #transplantation
Shashank Cingam retweeted
#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm
1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion.
Simultaneous JCO pub, highlighted NY Times
ascopubs.org/doi/10.1200/JCO…
nytimes.com/2025/06/03/healt…
Shashank Cingam retweeted
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia nature.com/articles/s41375-0…
Shashank Cingam retweeted
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina ashpublications.org/bloodadv…
Shashank Cingam retweeted
Audrey is immensely supportive. She is a constant and eager pool of information and institutional knowledge. She steps in immediately to cover her teammates' patients. She was able to help two new hires with grace and kindness.
Shashank Cingam retweeted
Honored to have delivered our abstract as an oral presentation at ASH '24. Teclistamab can be given safely and effectively in the community bringing the drug more directly to the patients who need it! @HealthTree @AimazAfrough @utswcancer @ldandersonjr @flatironhealth
Shashank Cingam retweeted
Say it with me: 'Arlo-cel' - GPRC5D -directed CAR T presented by @SusanBal9
We see a very high ORR (91%) at the 150 x 10^6 dose.
mPFS of 18 months
Skin, nail, taste changes seem less, and less prolonged. There is a known neurotoxicity (12% all grades, 7% grade 3-4) characterized by dizziness, ataxia, nystagmus, and/or dysarthria. #ASH24
Shashank Cingam retweeted
#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm
@thanosdimop






























